Interleukin-10 in cutaneous disorders: Implications for its pathophysiological importance and therapeutic use

Archives of Dermatological Research

Volumn 291, Issue 12, 1999, Pages 628-636

  Asadullah, Khusru ^a,b   Sabat, Robert ^a   Wiese, Anja ^a   Döcke, Wolf Dietrich ^a   Volk, Hans Dieter ^a   Sterry, Wolfram ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

^b BAYER PHARMA AG   (Germany)

Author keywords

Cytokines; Dermatology IL 10; Inflammation; Psoriasis

Indexed keywords

CALCIPOTRIOL; CALCITRIOL; FUMARIC ACID DERIVATIVE; GLUCOCORTICOID; INTERLEUKIN 10; LITHIUM; RECOMBINANT INTERLEUKIN 10;

BACTERIAL SUPERINFECTION; CLINICAL TRIAL; CONNECTIVE TISSUE DISEASE; DISEASE COURSE; ECZEMA; ERYTHEMA; HUMAN; IMMUNITY; META ANALYSIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PSORIASIS; REGULATORY MECHANISM; REVIEW; SKIN CANCER; SKIN DISEASE; SKIN INFLAMMATION; SKIN TUMOR;

EID: 0033505875     PISSN: 03403696     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004030050467     Document Type: Review

References (102)

1. 1. Abel EA, DiCicco LM, Orenberg EK, Fraki JE, Farber EM (1986) Drugs in exacerbation of psoriasis. J Am Acad Dermatol 15: 1007-1022
2. 2. Asadullah K, Döcke WD, Haeußler A, Sterry W, Volk HD (1996) Progression of mycosis fungoides is associated with increasing cutaneous expression of interleukin 10 mRNA. J Invest Dermatol 107: 833-837
3. 3. Asadullah K, Friedrich M, Döcke WD, Jahn S, Volk HD, Sterry W (1997) Enhanced expression of T-cell activation and natural killer cell antigens indicates systemic anti-tumor response in early primary cutaneous T-cell lymphoma (CTCL). J Invest Dermatol 108: 743-747
4. 4. Asadullah K, Schmid H, Friedrich M, Randow F, Volk HD, Sterry W, Döcke WD (1997) Influence of monomethylfumarate on monocytic cytokine formation - explanation for adverse and therapeutic effects in psoriasis? Arch Dermatol Res 289: 623-630
5. 5. Asadullah K, Sterry W, Stephanek K, Jasulaitis D, Leupold M, Audring H, Volk HD, Döcke WD (1998) IL-10 is a key cytokine in psoriasis: proof of principle by IL-10 therapy - a new therapeutic approach. J Clin Invest 101: 783-794
6. 6. Asadullah K, Döcke WD, Ebeling M, Friedrich M, Belbe G, Audring H, Volk HD, Sterry W (1999) Interleukin-10 treatment of psoriasis - clinical results of a phase II trial. Arch Dermatol 135: 187-192
7. 7. Asadullah K, Gellrich S, Haeußler-Quade A, Döcke WD, Friedrich M, Jahn S, Volk HD, Sterry W (2000) Cytokine expression in cutaneous B-cell lymphoma lesions. J Exp Dermatol (in press)
8. 8. Bécherel PA, Le Goff L, Ktorza S, Ouaaz F, Mencia-Huerta JM, Dugas B, Debré P, Mossalayi MD, Arock M (1995) Interleukin-10 inhibits IgE-mediated nitric oxide synthase induction and cytokine synthesis in normal human keratino-cytes. Eur J Immunol 25: 2992-2995
9. 9. Blay JY, Burdin N, Rousset F, Lenoir G, Biron P, Philip T, Banchereau J, Favrot MC (1993) Serum interleukin-10 in non-Hodgkin's lymphoma: a prognostic factor. Blood 82: 2169-2174
10. 10. Bos JD, Wierenga EA, Sillevis-Smitt JH, Heijden FL van der, Kapsenberg ML (1992) Immune dysregulation in atopic eczema. Arch Dermatol 128: 1509-1512
11. 11. Boyd AS, Morris LF, Phillips CM, Menter MA (1996) Psoriasis and pregnancy: hormone and immune system interaction. Int J Dermatol 35: 169-172
12. 12. Braun-Falco O, Plewig G, Wolf HH (eds) (1995) Atopie und atopisches Ekzem. In: Dermatologie und Venerologie, 4th edn. Springer, Berlin Heidelberg New York, pp 445-460
13. 13. Carson WE, Lindemann MJ, Baiocchi R, Linett M, Tan JC, Chou CC, Narula S, Caligiuri MA (1995) The functional characterization of interleukin-10 receptor expression on human natural killer cells. Blood 85: 3577-3585
14. 14. Cassatella MA, Meda L, Gasperini S, Calzetti F, Bonora S (1994) Interleukin-10 upregulates IL-1 receptor antagonist production from lipopolysaccharide-stimulated human polymorphonuclear leukocytes by delaying mRNA degradation. J Exp Med 179: 1695-1699
15. 15. Chan SC, Li SH, Hanifin JM (1993) Increased interleukin-4 production by atopic mononuclear leukocytes correlates with increased cyclic adenosine-monophosphate-phosphodiesterase activity and is reversible by phosphodiesterase inhibition. J Invest Dermatol 100: 681-684
16. 16. Chernoff AE, Granowitz EV, Shapiro L, Vannier E, Lonnemann G, Angel JB, Kennedy JS, Rabson AR, Wolff SM, Dinarello CA (1995) A randomized, controlled trial of IL-10 in humans. Inhibition of inflammatory cytokine production and immune responses. J Immunol 154: 5492-5499
17. 17. Cortes JE, Talpaz M, Cabanillas F, Seymour JF, Kurzrock R (1995) Serum levels of interleukin-10 in patients with diffuse large cell lymphoma: lack of correlation with prognosis. Blood 85: 2516-2520
18. 18. D'Andrea A, Aste-Amezaga M, Valiante NM, Ma X, Kubin M, Trinchieri G (1993) Interleukin 10 (IL-10) inhibits human lymphocyte interferon gamma-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. J Exp Med 178: 1041-1048
19. 19. Das NS, Chowdary TN, Sobhanadri C, Rao KV (1978) The effect of topical isoprenaline on psoriatic skin. Br J Dermatol 99: 197-200
20. 20. De Waal Malefyt R, Abrams J, Bennett B, Figdor CG, Vries JE de (1991) Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 174: 1209-1220
21. 21. De Waal Malefyt R, Haanen J, Spits H, Roncarolo MG, Velde A te, Figdor C, Johnson K, Kastelein R, Yssel H, Vries JE de (1991) Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med 174: 915-924
22. 22. Dummer R, Kohl O, Gillessen J, Kägi M, Burg G (1993) Peripheral blood mononuclear cells in patients with nonleukemic cutaneous T-cell lymphoma. Arch Dermatol 129: 433-436
23. 23. Dummer R, Heald PW, Nestle FO, Ludwig E, Laine E, Hemmi S, Burg G (1996) Sézary syndrome T-cell clones display T-helper 2 cytokines and express the accessory factor-1 (interferon-gamma receptor beta-chain). Blood 88: 1383-1389
24. 24. Dummer W, Bastian BC, Ernst N, Schnalze C, Schwaaf A, Brocker EB (1996) Interleukin-10 production in malignant melanoma: preferential detection of IL-10-secreting tumor cells in metastatic lesions. Int J Cancer 66: 607-610
25. 25. Edelson RL (1980) Cutaneous T cell lymphoma: mycosis fungoides, Sezary syndrome, and other variants. J Am Acad Dermatol 2: 89-106
26. 26. Enk AH, Katz SI (1992) Identification and induction of keratinocyte-derived IL-10. J Immunol 149: 92-95
27. 27. Enk AH, Angeloni VL, Udey MC, Katz SI (1993) Inhibition of Langerhans cell antigen-presenting function by IL-10. A role for IL-10 in induction of tolerance. J Immunol 151: 2390-2398
28. 28. Enk CD, Sredni D, Blauvelt A, Katz SI (1995) Induction of IL-10 gene expression in human keratinocytes by UVB exposure in vivo and in vitro. J Immunol 154: 4851-4856
29. 29. Finbloom DS, Winestock KD (1995) IL-10 induces the tyrosine phosphorylation of tyk2 and Jak1 and the differential assembly of STAT1 alpha and STAT3 complexes in human T cells and monocytes. J Immunol 155: 1079-1090
30. 30. Fiorentino DF, Bond MW, Mosmann TR (1989) Two types of mouse T-helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med 170: 2081-2095
31. 31. Fiorentino DF, Zlotnik A, Mosmann TR, Howard M, O'Garra A (1991) IL-10 inhibits cytokine production by activated macrophages. J Immunol 147: 3815-3822
32. 32. Fiorentino DF, Zlotnik A, Vieira P, Mosmann TR, Howard M, Moore KW, O'Garra A (1991) IL-10 acts on antigen-presenting cell to inhibit cytokine production by Th1 cells. J Immunol 146: 3444-3451
33. 33. Fleming SB, McCaughan CA, Andrews AE, Nash AD, Mercer AA (1997) A homolog of interleukin-10 is encoded by the poxvirus orf virus. J Virol 71: 4857-4861
34. 34. Giacalone B, D'Auria L, Bonifati C, Ferraro C, Riccardi E, Mussi A, D'Agosto G, Cordiali-Fei P, Ameglio F (1998) Decreased interleukin-7 and transforming growth factor-beta1 levels in blister fluids as compared to the respective serum levels in patients with bullous pemphigoid. Opposite behavior of TNF-alpha, interleukin-4 and interleukin-10. Exp Dermatol 7: 157-161
35. 35. Gilhar A, Grossman N, Kahanovicz S, Reuveni H, Cohen S, Eitan A (1996) Antiproliferative effect of pentoxifylline on psoriatic and normal epidermis. In vitro and in vivo studies. Acta Derm Venereol (Stockh) 76: 437-441
36. 36. Grewe M, Gyufko K, Krutmann J (1995) Interleukin-10 production by cultured human keratinocytes: regulation by ultra-violet B and ultraviolet AI radiation. J Invest Dermatol 104: 3-6
37. 37. Hart PH, Hunt EK, Bonder CS, Watson CM, Finlay-Jones JJ (1996) Regulation of surface and soluble TNF receptor expression on human monocytes and synovial fluid macrophages by IL-4 and IL-10. J Immunol 157: 3672-3680
38. 38. Hasegawa M, Fujimoto M, Kikuchi K, Takehara K (1997) Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis. J Rheumatol 24: 328-332
39. 39. Ho AS, Liu Y, Khan TA, Hsu DH, Bazan JF, Moore KW (1993) A receptor for interleukin 10 is related to interferon receptors. Proc Natl Acad Sci U S A 90: 11267-11271
40. 40. Hsu DH, De Waal Malefyt R, Fiorentino DF, Dang MN, Vieira P, De Vries J, Spits H, Mosmann TR, Moore KW (1990) Expression of interleukin-10 activity by Epstein-Barr virus protein BCRF1. Science 250: 830-832
41. 41. Ishida H, Muchamuel T, Sakaguchi S, Andrade S, Menon S, Howard M (1994) Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice. J Exp Med 179: 305-310
42. 42. Jenkins JK, Malyak M, Arend WP (1994) The effects of interleukin-10 on interleukin-1 receptor antagonist and interleukin-1 beta production in human monocytes and neutrophils. Lymphokine Cytokine Res 13: 47-54
43. 43. Jurlander J, Lai CF, Tan J, Chou CC, Geisler CH, Schriber J, Blumenson LE, Narula SK, Baumann H, Caligiuri MA (1997) Characterization of interleukin-10 receptor expression on B-cell chronic lymphocytic leukemia cells. Blood 89: 4146-4152
44. 44. Kang K, Hammerberg C, Meunier L, Cooper KD (1994) CD11b+ macrophages that infiltrate human epidermis after in vivo ultraviolet exposure potently produce IL-10 and represent the major secretory source of epidermal IL-10 protein. J Immunol 153: 5256-5264
45. 45. Kang S, Yi S, Griffiths CEM, Fancher L, Hamilton TA, Choi JH (1998) Calcipotriene-induced improvement in psoriasis is associated with reduced interleukin-8 and increased interleukin-10 levels within lesions. Br J Dermatol 138: 77-83
46. 46. Kim J, Modlin RL, Moy RL, Dubinett SM, McHugh T, Nickoloff BJ, Uyemura K (1995) IL-10 production in cutaneous basal and squamous cell carcinomas. A mechanism for evading the local T cell immune response. J Immunol 155: 2240-2247
47. 47. Kondo S, McKenzie RC, Sauder DN (1994) Interleukin-10 inhibits the elicitation phase of allergic contact hypersensitivity. J Invest Dermatol 103: 811-814
48. 48. Kotenko SV, Krause CD, Izotova LS, Pollack BP, Wu W, Pestka S (1997) Identification and functional characterization of a second chain of the interleukin-10 receptor complex. EMBO J 16: 5894-5903
49. 49. Krüger-Krasagakes S, Krasagakis K, Garbe C, Schmitt E, Hüls C, Blankenstein T, Diamantstein T (1994) Expression of inlerleukin 10 in human melanoma. Br J Cancer 70: 1182-1185
50. 50. Kuhn R, Lohler J, Rennick D, Rajewsky K, Muller W (1993) Interleukin-10-deficient mice develop chronic enterocolitis. Cell 75: 263-274
51. 51. Lin TJ, Befus AD (1997) Differential regulation of mast cell function by IL-10 and stem cell factor. J Immunol 159: 4015-4023
52. 52. Liu Y, Wei SH, Ho AS, De Waal Malefyt R, Moore KW (1994) Expression cloning and characterization of a human IL-10 receptor. J Immunol 152: 1821-1829
53. 53. Llorente L, Zou W, Levy Y, Richard-Patin Y, Wijdenes J, Alcocer-Varela J, Morel-Fourier B, Brouet JC, Alarcon-Segovia D, Galanaud P, Emilie D (1995) Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. J Exp Med 181: 839-844
54. 54. Llorente L, Garcia-Padilla C, Richaud-Patin Y, Wijdenes J, Cardiel M, Varela JA, Alarcon-Segovia D, Galanaud P, Emilie D (1999) Treatment of systemic lupus erythematosus with an anti-IL-10 monoclonal antibody: clinical and biological aspects. Presentation at The Second International IL-10 Workshop. 27-29 May 1999, Milan
55. 55. Matsuda M, Salazar F, Petersson M, Masucci G, Hansson J, Pisa P, Zhang QJ, Masucci MG, Kiessling R (1994) Interleukin 10 pretreatment protects target cells from tumor-and allo-specific cytotoxic T cells and downregulates HLA class I expression. J Exp Med 180: 2371-2376
56. 56. Meisel C, Vogt K, Platzer C, Randow F, Liebenthal C, Volk HD (1996) Differential regulation of monocytic tumor necrosis factor-alpha and interleukin-10 expression. Eur J Immunol 26: 1580-1586
57. 3 and calcipotriol induce IL-10 receptor gene expression in human epidermal cells. Inflamm Res 46: 32-34
58. 58. Michel G, Mirmohammadsadegh A, Olasz E, Jarzebska-Deussen B, Muschen A, Kemeny L, Abts HF, Ruzicka T (1997) Demonstration and functional analysis of IL-10 receptors in human epidermal cells: decreased expression in psoriatic skin, down-modulation by IL-8, and up-regulation by an antipsoriatic glucocorticosteroid in normal cultured keratino-cytes. J Immunol 159: 6291-6297
59. 59. Mitra RS, Judge TA, Nestle FO, Turka LA, Nickoloff BJ (1995) Psoriatic skin-derived dendritic cell function is inhibited by exogenous IL-10. Differential modulation of B7-1 (CD80) and B7-2 (CD86) expression. J Immunol 154: 2668-2677
60. 60. Mussi A, Bonifati C, Carducci M, Viola M, Tomaselli R, Sacerdoti G, Fazio M, Ameglio F (1994) IL-10 levels are decreased in psoriatic lesional skin as compared to the psoriatic lesion-free and normal skin suction blister fluids. J Biol Regul Homeost Agents 8: 117-120
61. 61. Nakajima H, Gleich GJ, Kita H (1996) Constitutive production of IL-4 and IL-10 and stimulated production of IL-8 by normal peripheral blood eosinophils. J Immunol 156: 4859-4866
62. 62. Nickoloff BJ, Fivenson DP, Kunkel SL, Strieter RM, Turka LA (1994) Keratinocyte interleukin-10 expression is upregulated in tape-stripped skin, poison ivy dermatitis, and Sezary syndrome, but not in psoriatic plaques. Clin Immunol Immunopathol 73: 63-68
63. 63. Norris DA, Travers JB, Leung DY (1997) Lymphocyte activation in the pathogenesis of psoriasis. J Invest Dermatol 109: 1-4
64. 64. Öckenfels HM, Wagner SN, Keim-Maas C, Funk R, Nussbaum G, Goos M (1996) Lithium and psoriasis: cytokine modulation of cultured lymphocytes and psoriatic keratinocytes by lithium. Arch Dermatol Res 288: 173-178
65. 65. Ohmen JD, Hanifin JM, Nickoloff BJ, Rea TH, Wyzykowski R, Kim J, Jullien D, McHugh T, Nassif AS, Chan SC, Modlin RL (1995) Overexpression of IL-10 in atopic dermatitis. Contrasting cytokine patterns with delayed-type hypersensitivity reactions. J Immunol 154: 1956-1963
66. 66. Park YB, Lee SK, Kim DS, Lee J, Lee CH, Song CH (1998) Elevated interleukin-10 levels correlated with disease activity in systemic lupus erythematosus. Clin Exp Rheumatol 16: 283-288
67. 67. Pistoia V (1997) Production of cytokines by human B cells in health and disease. Immunol Today 18: 343-350
68. 68. Platzer C, Meisel C, Vogt K, Platzer M, Volk HD (1995) Up-regulation of monocytic IL-10 by tumor necrosis factor-alpha and cAMP elevating drugs. Int Immunol 7: 517-523
69. 69. Pretolani M, Goldman M (1997) IL-10: a potential therapy for allergic inflammation? Immunol Today 18: 277-280
70. 70. Reich K, Bruck M, Grafe A, Vente C, Neumann C, Garbe C (1998) Treatment of psoriasis with interleukin-10 (letter). J Invest Dermatol 111: 1235-1236
71. 71. Reineke U, Sabat R, Volk HD, Schneider-Mergener J (1998) Mapping of the interleukin-10/interleukin-10 receptor combining site. Protein Sci 7: 951-960
72. 72. Renz H, Jujo K, Bradley KL, Domenico J, Gelfand EW, Leung DY (1992) Enhanced IL-4 production and IL-4 receptor expression in atopic dermatitis and their modulation by interferon-gamma. J Invest Dermatol 99: 403-408
73. 73. Rode HJ, Bugert JJ, Handermann M, Schnitzler P, Kehm R, Janssen W, Delius H, Darai G (1994) Molecular characterization and determination of the coding capacity of the genome of equine herpesvirus type 2 between the genome coordinates 0.235 and 0.258 (the EcoRI DNA fragment N; 4.2kbp). Virus Genes 9: 61-75
74. 74. Romagnani S (1995) Biology of human TH1 and TH2 cells. J Clin Immunol 15: 121-129
75. 75. Schlaak JE, Buslau M, Jochum W, Hermann E, Girndt M, Gallati H, Meyer zum Büschenfelde KH, Fleischer B (1994) T cells involved in psoriasis vulgaris belong to the Th 1 subset. J Invest Dermatol 102: 145-149
76. 76. Schmidt E, Bastian B, Dummer R, Tony HP, Bröcker EB, Zillikens D (1996) Detection of elevated levels of IL-4, IL-5, and IL-10 in blister fluid of bullous pemphigoid. Arch Dermatol Res 228: 353-357
77. 77. Schreiber S, Heinig T, Thiele HG, Raedler A (1995) Immunoregulatory role of interleukin 10 in patients with inflammatory bowel disease. Gastroenterology 108: 1432-1444
78. 78. Schwarz A, Grabbe S, Riemann H, Aragane Y, Simon M, Manon S, Andrade S, Luger TA, Zlotnik A, Schwarz T (1994) In vivo effects of interleukin-10 on contact hypersensitivity and delayed type hypersensitivity reactions. J Invest Dermatol 103: 211-216
79. 79. Spencer SD, Di Marco F, Hooley J, Pitts-Meek S, Bauer M, Ryan AM, Sordat B, Gibbs VC, Aguet M (1998) The orphan receptor CRF2-4 is an essential subunit of the interleukin 10 receptor. J Exp Med 187: 571-578
80. 80. Spits H, De Waal Malefyt R (1992) Functional characterization of human IL-10. Int Arch Allergy Immunol 99: 8-15
81. 81. Stasi R, Zinzani PL, Galieni P, Lauta VM, Damasio E, Dispensa E, Dammacco F, Papa G, Tura S (1994) Prognostic value of serum IL-10 and soluble IL-2 receptor levels in aggressive non-Hodgkin's lymphoma. Br J Haematol 88: 770-777
82. 82. Stasi R, Zinzani L, Galieni P, Lauta VM, Damasio E, Dispensa E, Dammacco F, Tura S, Papa G (1994) Detection of soluble interLeukin-2 receptor and interleukin-10 in the serum of patients with aggressive non-Hodgkin's lymphoma. Identification of a subset at high risk of treatment failure. Cancer 74: 1792-1800
83. 83. Takanaski S, Nonaka R, Xing Z, O'Byrne P, Dolovich J, Jordana M (1994) Interleukin 10 inhibits lipopolysaccharide-induced survival and cytokine production by human peripheral blood eosinophils. J Exp Med 180: 711-715
84. 84. Tan JC, Indelicato SR, Narula SK, Zavodny PJ, Chou CC (1993) Characterization of interleukin-10 receptors on human and mouse cells. J Biol Chem 268: 21053-21059
85. 85. Teunissen MB, Koomen CW, Jansen J, de Waal Malefyt R, Schmitt E, Van den Wijngaard RM, Das PK, Bos JD (1997) In contrast to their murine counterparts, normal human keratinocytes and human epidermoid cell lines A431 and HaCaT fail to express IL-10 mRNA and protein. Clin Exp Immunol 107: 213-223
86. 86. Thompson-Snipes L, Dhar V, Bond MW, Mosmann TR, Moore KW, Rennick DM (1991) Interleukin 10: a novel stimulatory factor for mast cells and their progenitors. J Exp Med 173: 507-510
87. 87. Uejima Y, Takahashi K, Komoriya K, Kurozumi S, Ochs HD (1996) Effect of interleukin-10 on anti-CD40-and interleukin-4-induced immunoglobulin E production by human lymphocytes. Int Arch Allergy Immunol 110: 225-232
88. 88. Valdimarsson H, Baker BS, Johnsdottir I, Fry L (1985) Psoriasis: a disease of abnormal keratinocyte proliferation induced by T lymphocytes. Immunol Today 7: 256-259
89. 89. Van Deventer SJ, Elson CO, Fedorak RN (1997) Multiple doses of intravenous interleukin-10 in steroid refractory Crohn's disease. Crohn's Disease Study Group. Gastroenterology 113: 383-389
90. 90. Van Reijsen FC, Bruijnzeel Koomen CA, Kalthoff FS, Maggi E, Romagnani S, Westland JK, Mudde GC (1992) Skin-derived aeroallergen-specific T-cell clones of Th2 phenotype in patients with atopic dermatitis. J Allergy Clin Immunol 90: 184-193
91. 91. Vora M, Romero LI, Karasek MA (1996) Interleukin-10 induces E-selectin on small and large blood vessel endothelial cells. J Exp Med 184: 821-829
92. 92. Weber-Nordt RM, Meraz MA, Schreiber RD (1994) Lipopolysaccharide-dependent induction of IL-10 receptor expression on murine fibroblasts. J Immunol 153: 3734-3744
93. 93. Wegmann TG, Lin H, Guilbert L, Mosmann TR (1993) Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a Th2 phenomenon? Immunol Today 14: 353-356
94. 94. Weinstein GD (1996) Can immunomodulatory molecules work topically for psoriasis? J Invest Dermatol 106: 589
95. 95. Wissing KM, Morelon E, Legendre C, De-Pauw L, LeBeaut A, Grint P, Maniscalki M, Ickx B, Vereerstraeten P, Chatenoud L, Kreis H, Goldman M, Abramowicz D (1997) A pilot trial of recombinant human interleukin-10 in kidney transplant recipients receiving OKT3 induction therapy. Transplantation 64: 999-1006
96. 96. Woiciechowsky C, Asadullah K, Nestler D, Eberhardt B, Platzer C, Schöning B, Glöckner F, Lanksch WR, Volk HD, Döcke WD (1998) Sympathetic activation triggers systemic interleukin-10 release in immunodepression induced by brain injury. Nat Med 4: 808-813
97. 97. Wölfer LU, Goerdt S, Schröder K, Zouboulis CC, Orfanos CE (1996) Interferon-alpha-induced psoriasis vulgaris. Hautarzt 47: 124-128
98. 98. Yagi H, Tokura Y, Furukawa F, Takigawa M (1996) Th2 cytokine mRNA expression in primary cutaneous CD30-positive lymphoproliferative disorders: successful treatment with recombinant interferon-gamma. J Invest Dermatol 107: 827-832
99. 99. Yue FY, Dummer R, Geertsen R, Hofbauer G, Laine E, Manolio S, Burg G (1997) Interleukin-10 is a growth factor for human melanoma cells and down-regulates HLA class I, HLA class II and ICAM-1 molecules. Int J Cancer 71: 630-637
100. 100. Zdanov A, Schalk-Hihi C, Gustchina A, Tsang M, Weatherbee J, Wlodawer A (1995) Crystal structure of interleukin-10 reveals the functional dimer with an unexpected topological similarity to interferon gamma. Structure 3: 591-601
101. 101. Zdanov A, Schalk-Hihi C, Menon S, Moore KW, Wlodawer A (1997) Crystal structure of Epstein-Barr virus protein BCRF1, a homolog of cellular interleukin-10. J Mol Biol 268: 460-467
102. 102. Zhu K, Mrowietz U (1999) Regulation of IL-10 secretion and mRNA expression by 1,25-dihydroxyvitamin D3 and its analogue tacalcitol in monocyte-derived dendritic cells (abstract). J Invest Dermatol 113: 474